In a mouse model of RCC, anti-PD-L1 combined with everolimus was more effective for tumor regression than individual treatment due to the upregulation of PD-L1 in tumor cells, which increased the tumor-infiltrating CD8+ T cells [73]. The gene discussed is CD274; the disease is neoplasm.